Propanc Biopharma, Inc. (OTCQB:PPCB)

The #Propanc Difference   Instead of targeting tumor cell death, we focus on inducing cell differentiation. We convince malignant cells to stop proliferating and encourage them to continue their work as a specific cell type.   What makes us different? Using Differentiation Therapy to Combat Cancer   Instead of targeting tumor cell death, we are focusing on inducing cell differentiation. By convincing malignant cells to stop proliferating, we are encouraging them to return to do their work as a specific cell type.   Visit our website to learn more: https://lnkd.in/g2hGmmR7   #propanc #ppcb #biopharma #cancer #oncology  Propanc Biopharma, Inc. (OTCQB:PPCB)

May is National #Cancer Research Month, a time to reflect on the significant strides being made in the field of cancer research.    At Propanc Biopharma, Inc. (OTCQB:PPCB), we are dedicated to pioneering innovative treatments for pancreatic, ovarian, and colorectal cancers. Our commitment is driven by the urgent need to develop effective therapies that can prevent disease progression and improve the quality of life for patients worldwide.    This month, we celebrate the progress and the persistent efforts of researchers and healthcare professionals globally.   #NationalCancerResearchMonth #CancerResearch #PropancBiopharma  

  Propanc Biopharma, Inc. (OTCQB:PPCB) is dedicated to the development of PRP, a therapy based on pancreatic proenzymes aimed at preventing tumor recurrence and metastasis. As we move through the drug development pipeline, PRP has completed preclinical development and is now entering clinical phase with a Phase 1B, First-In-Human study in advanced cancer patients suffering from solid tumors.    Our approach focuses on a treatment that is effective for long-term use, suitable for patients diagnosed with cancer and potentially for those at high risk of developing cancer. Our commitment to providing an anti-cancer product that is both effective and well-tolerated underscores our response to the urgent need for better cancer treatments.   www.propanc.com   #propanc #ppcb #biopharma #cancer #oncology 

How has Propanc Biopharma optimized the formulation of their lead asset? We invite you to listen as Dr. Ralf Brandt, Propanc’s Scientific Advisory Board Member & Co-Inventor describes the process for taking the formulation from that compassionate use study that observed such positive results, and how the team further improved that same formulation with the goal of seeing even more efficacious results!   #propanc #ppcb #biopharma #cancer #oncology

Effects of sleep disturbance, cancer-related fatigue, and psychological distress on breast cancer patients’ quality of life: a prospective longitudinal observational study   More attention has gone to researching the #cancer-related fatigue (CRF)–sleep disturbance (SD)–psychological distress (PD) symptom cluster in breast cancer patients during the chemotherapy period, but the change trend and heterogeneous development track in the whole treatment stage remain unclear, and it is also unclear whether the appearance of and changes in one symptom cause changes in other symptoms and #qualityoflife (QoL). This study, using breast cancer patients’ data collected through a validated questionnaire, examined the relationships between SD, CRF, PD, and QoL using latent growth modeling analyses.   https://lnkd.in/g-E2mbwH   This study highlights the complex challenges patients face beyond their medical treatments. Understanding these factors is essential for developing more comprehensive care strategies that address both the physical and psychological components of patient health.   #propanc #ppcb #biopharma #cancer #oncology   James Nathanielsz Propanc Biopharma, Inc. (OTCQB:PPCB)

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.   Propanc Biopharma, Inc. (OTCQB:PPCB) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.   #propanc #ppcb #biopharma #cancer #oncology  James Nathanielsz    

Propanc Biopharma, Inc. (OTCQB:PPCB) Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office   Propanc Biopharma, Inc. (OTCQB:PPCB), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s "composition of proenzymes for cancer treatment," patent was received from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes (trypsinogen and chymotrypsinogen) contained in the PRP formulation. This is the fourth European patent granted and after validation in selected countries across Europe, will result in the Company’s IP portfolio growing to 94 patents filed in major global jurisdictions.   https://lnkd.in/gjvFQEzx   #propanc #ppcb #biopharma #cancer #oncology James Nathanielsz  

ICYMI: You can now watch our first virtual event on-demand! Hear directly from Dr. Julian Kenyon below as he discusses in detail what was observed in Propanc’s compassionate use study, who the patients were, and why he believes the results are “truly extraordinary!”   #propanc #ppcb #biopharma #cancer #oncology

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing   Propanc Biopharma, Inc. (OTCQB:PPCB), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing. Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work. In this week’s episode, Mr. Nathanielsz discusses the competitive advantage of the Company and its enzyme treatment for metastatic cancer.   https://lnkd.in/gGY3pvmJ   #propanc #ppcb #biopharma #cancer #oncology 

How is Propanc treating cancer differently? What makes their compassionate use data so compelling? Learn about the innovative approach being taken by the company to develop new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancers and how they are leveraging more than 100 years of scientific study of enzyme use to develop a truly novel, de-risked approach to cancer treatment. Propanc's management team joins Andrew Eriksen of Allele Capital to discuss the exciting data produced by the Company's compassionate use study and what comes next for the company as they develop their lead asset, PRP.